European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts
Executive Summary
Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes
You may also be interested in...
Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
After Elections, Germany’s Pharma Industry Faces Uncertain Future
German elections have led to the possibility of several coalition government constellations, but none are particularly good for the pharmaceutical industry.
German Drug Report Could Mean More Pressure On Pharma Revenues
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.